Search results
Novo’s Blockbuster Obesity Drug Wegovy Under Fire in Denmark
Bloomberg· 8 hours agoA Danish drug oversight panel advised doctors to restrict prescriptions of Novo Nordisk A/S’s...
Michigan’s largest insurer to drop weight-loss drug coverage
Chicago Tribune· 1 day agoWeight-loss drugs from Novo Nordisk A/S and Eli Lilly & Co. will lose coverage under many plans run...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 1 day agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 1 day agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Weight Loss Drugs Like Wegovy and Ozempic May Change Sense of Taste
Prevention via Yahoo News· 8 hours agoWeight loss drugs like Wegovy and Ozempic may change sense of taste and how the brain reacts to...
Thousands in one state to lose weight loss drug coverage
Newsweek· 5 hours agoThousands of people in Michigan who use popular weight loss drugs will soon lose their coverage for...
Anti-obesity drugs will be 2024’s defining trend
Clinical Trials Arena via Yahoo Finance· 1 day agoGlobalData’s latest update notes the impact of the growing anti-obesity market, personalised medicines, real-world evidence, and cell and gene therapies.
Why Blue Cross of Michigan is axing coverage of popular weight loss drugs
Detroit News· 1 day agoBlue Cross Blue Shield of Michigan is dropping coverage of popular weight loss drugs, citing...
Is Ozempic an Obesity Drug, or an Everything Drug?
The Atlantic· 2 days agoThere’s no such thing as a miracle cure for weight loss, but the latest obesity drugs seem to come pretty close. People who take Ozempic or other weekly...
New KFF Analysis Finds Costly GLP-1 Drugs ( includes Wegovy and Ozempic) are Rarely Covered for...
Sierra Sun Times· 7 hours agoAffordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy ...